Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Turn Therapeutics Inc. (TTRX)

Turn Therapeutics names former CDC Director Robert Redfield as Chief Scientific Officer

Neutral Impact 3 of 5 leadership Written later

Turn Therapeutics appointed Robert R. Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, as Chief Scientific Officer. The filing says he will contribute to the scientific and clinical strategy for GX-03 across several indications.

Key points

  • Robert R. Redfield, M.D., appointed Chief Scientific Officer, announced September 9, 2026
  • Redfield served as the 18th Director of the U.S. Centers for Disease Control and Prevention, from 2018 to 2021
  • GX-03 is being evaluated in atopic dermatitis and developed for onychomycosis, hidradenitis suppurativa, and potential additional indications
  • Stephen M. Hahn, M.D., former FDA Commissioner, is listed as Executive Clinical and Regulatory Lead

The filing

CompanyTurn Therapeutics Inc. (TTRX)
Form8-K, current report
Filed with the SECSep 9, 2026, 8:10 AM ET
Accession number0001213900-26-098224

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.